...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: ZEN-3694 Single Agent Trial Status

Bear.

Yes, completion of BoM, various orphan trials at RVX and continued development at Zenith.

My apologies. I have mixed up the companies in my response and I should be more precise.

Toinv

Share
New Message
Please login to post a reply